Biotech | March 12, 2024
USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
It is the first autotaxin inhibitor to be investigated in cancer patients
It is the first autotaxin inhibitor to be investigated in cancer patients
These approvals mark significant progress for Venus Remedies in expanding its market presence
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
The validations confirm the completion of the applications and commence the scientific review process
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Connecting new production and consumption areas of chilled food by low-carbon transportation services
Collaborative Research in AYUSH is extremely important as it bridges the gap between traditional knowledge and modern scientific research
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Subscribe To Our Newsletter & Stay Updated
